181 related articles for article (PubMed ID: 17375033)
1. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Liu G; Gurubhagavatula S; Zhou W; Wang Z; Yeap BY; Asomaning K; Su L; Heist R; Lynch TJ; Christiani DC
Pharmacogenomics J; 2008 Apr; 8(2):129-38. PubMed ID: 17375033
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Tiseo M; Capelletti M; De Palma G; Franciosi V; Cavazzoni A; Mozzoni P; Alfieri RR; Goldoni M; Galetti M; Bortesi B; Bozzetti C; Loprevite M; Boni L; Camisa R; Rindi G; Petronini PG; Ardizzoni A
J Thorac Oncol; 2008 Oct; 3(10):1104-11. PubMed ID: 18827605
[TBL] [Abstract][Full Text] [Related]
3. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
[TBL] [Abstract][Full Text] [Related]
4. Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R; Moran T; Queralt C; Porta R; Cardenal F; Camps C; Majem M; Lopez-Vivanco G; Isla D; Provencio M; Insa A; Massuti B; Gonzalez-Larriba JL; Paz-Ares L; Bover I; Garcia-Campelo R; Moreno MA; Catot S; Rolfo C; Reguart N; Palmero R; Sánchez JM; Bastus R; Mayo C; Bertran-Alamillo J; Molina MA; Sanchez JJ; Taron M;
N Engl J Med; 2009 Sep; 361(10):958-67. PubMed ID: 19692684
[TBL] [Abstract][Full Text] [Related]
5. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.
Ichihara S; Toyooka S; Fujiwara Y; Hotta K; Shigematsu H; Tokumo M; Soh J; Asano H; Ichimura K; Aoe K; Aoe M; Kiura K; Shimizu K; Date H; Shimizu N
Int J Cancer; 2007 Mar; 120(6):1239-47. PubMed ID: 17192902
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P
Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
[TBL] [Abstract][Full Text] [Related]
7. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
Damyanov D; Koynov K; Naseva E; Bichev S
J BUON; 2015; 20(1):136-41. PubMed ID: 25778308
[TBL] [Abstract][Full Text] [Related]
8. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
[TBL] [Abstract][Full Text] [Related]
9. EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Winther Larsen A; Nissen PH; Meldgaard P; Weber B; Sorensen BS
Lung Cancer; 2014 Sep; 85(3):435-41. PubMed ID: 25017413
[TBL] [Abstract][Full Text] [Related]
10. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.
Ma F; Sun T; Shi Y; Yu D; Tan W; Yang M; Wu C; Chu D; Sun Y; Xu B; Lin D
Lung Cancer; 2009 Oct; 66(1):114-9. PubMed ID: 19201048
[TBL] [Abstract][Full Text] [Related]
12. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
13. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
Gregorc V; Hidalgo M; Spreafico A; Cusatis G; Ludovini V; Ingersoll RG; Marsh S; Steinberg SM; Viganò MG; Ghio D; Villa E; Sparreboom A; Baker SD
Clin Pharmacol Ther; 2008 Mar; 83(3):477-84. PubMed ID: 17713473
[TBL] [Abstract][Full Text] [Related]
14. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
[TBL] [Abstract][Full Text] [Related]
15. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
[TBL] [Abstract][Full Text] [Related]
16. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Song Z; Zhang Y
J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
